Everolimus Tablet
Product Images NDC 70377-011

Product Visual Gallery

This gallery contains 6 technical images submitted to the FDA as part of the official labeling for Everolimus (NDC 70377-011). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Biocon Pharma Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

2.5 mg Everolimus Tablets

Packaging label for Everolimus Tablets 2.5 mg by Biocon Pharma Inc. The label indicates a carton containing 28 tablets in 4 individual blister cards of 7 tablets each. The label displays the NDC 70377-010-22 and notes the prescription-only status. Storage directions and manufacturer details are printed on the carton.*

FDA Label Image

Everolimus Structure

Chemical structure of the active ingredient everolimus, displayed as a complex molecular diagram with multiple rings, bonds, and functional groups, corresponding to its molecular composition in the EVEROLIMUS oral tablet formulation by Biocon Pharma Inc.*

FDA Label Image

Everolimus Tablets 5mg

Everolimus Tablets 5 mg oral tablets packaging label from Biocon Pharma Inc. The label indicates 28 tablets per carton, divided into 4 blister cards containing 7 tablets each. It includes storage instructions, manufacturer information, and the NDC 70377-011-22. The packaging is primarily white with blue and brown accents and the Biocon logo.*

FDA Label Image

Everoliomus Tablets 10mg

Packaging label for Everolimus Tablets 10 mg by Biocon Pharma Inc. The label includes product name, strength (10 mg), dosage form (tablets), quantity (28 tablets), NDC 70377-013-22, and manufacturer details. The label is white and blue with orange highlight for strength and displays the Biocon logo.*

FDA Label Image

Fig 1

A Kaplan-Meier survival curve comparing progression-free survival probability over time (in months) between two groups: one receiving Everolimus 10 mg plus exemestane and the other receiving placebo plus exemestane. The chart shows higher survival probability for the Everolimus group with accompanying statistics including hazard ratio, confidence interval, median survival times, and logrank p value.*

FDA Label Image

Everolimus Tablets 7.5 mg

Packaging label for Everolimus Tablets 7.5 mg by Biocon Pharma Inc. The label displays the NDC 70377-012-22 and indicates that each tablet contains 7.5 mg of everolimus. The carton includes 28 tablets, divided into 4 individual blister cards of 7 tablets each. The label also features storage instructions, manufacturing details for Biocon Pharma Inc. and Biocon Pharma Limited, and the Rx only designation.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.